Clene Inc.
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Clene Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 3.30 $ to 12.50 $ · Last price: 4.10 $ (As of: September 28, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/29/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Packaged Foods
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Clene Inc. CLNN | 0.1 | – | -1.1 | 70.1 | -13,740.0 | -41.5 | -31.0 |
| JBS N.V. JBS | 38.2 | 11.2 | 6.0 | 11.8 | 2.5 | 13.0 | -14.4 |
| Kraft Heinz Co KHC | 27.8 | – | 13.1 | 33.5 | 20.7 | -3.5 | -2.2 |
| General Mills Inc GIS | 18.2 | 8.4 | 21.2 | 33.7 | 19.2 | -1.9 | -27.7 |
| McCormick & Company Incorporated MKC-V | 13.4 | 8.3 | 12.9 | 38.9 | 17.4 | 1.7 | -20.6 |
| McCormick & Company Incorporated MKC | 13.2 | 8.7 | 12.9 | 38.9 | 17.4 | 1.7 | -23.4 |
| The J. M. Smucker Company SJM | 12.5 | – | 14.8 | 38.0 | 18.5 | 3.7 | 16.8 |
| Hormel Foods Corporation HRL | 11.1 | 27.0 | 14.8 | 15.7 | 11.1 | 1.6 | -15.0 |
| Darling Ingredients Inc DAR | 9.7 | 44.2 | 9.2 | 26.3 | 8.1 | 7.4 | 95.0 |
| Median of companies shown | 13.2 | 9.9 | 12.9 | 33.7 | 17.4 | 1.7 | -15.0 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | – | 0 | 0 | 0.00 | – | – | – |
| 2018 | – | 0 | 0 | -0.09 | 0 | 5 | 47 |
| 2019 | 0 | -16 | -16 | -4.65 | -13 | 5 | 15 |
| 2020 | 0 | -20 | -19 | -5.51 | -19 | 0 | 68 |
| 2021 | 1 | -50 | -10 | -3.16 | -35 | 13 | 63 |
| 2022 | 0 | -48 | -30 | -9.18 | -39 | 3 | 44 |
| 2023 | 1 | -41 | -50 | -9.43 | -30 | 13 | 52 |
| 2024 | 0 | -33 | -39 | -5.67 | -21 | -9 | 27 |
| 2025 | 0 | -23 | -26 | -2.65 | -19 | -18 | 18 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q2 | -1.30 | 78.50 | 0 | -66.20 | -7,456.00 | -6 | -6 |
| 2024: Q3 | -1.11 | 27.90 | 0 | -19.40 | -9,179.30 | -3 | -3 |
| 2024: Q4 | -1.36 | -2,174.30 | 0 | -46.50 | -14,889.00 | -5 | -5 |
| 2025: Q1 | -0.50 | 67.30 | 0 | 11.00 | -927.20 | -5 | -5 |
| 2025: Q2 | -0.78 | 40.00 | 0 | -70.30 | -27,477.80 | -5 | -5 |
| 2025: Q3 | -0.85 | 23.40 | 0 | -82.80 | -58,513.30 | -4 | -4 |
| 2025: Q4 | -0.78 | 42.90 | 0 | -15.40 | -11,981.80 | -5 | -5 |
| 2026: Q1 | -0.69 | -38.00 | 0 | -81.50 | -53,940.00 | -5 | -5 |
| 2026: Q2 | -1.08 | -38.50 | 0 | – | -13,400.00 | -3 | -3 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Growth
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.62 | -2.78 – -2.46 | 0 | -2.1% | 2 |
| 12/31/2027 | -2.44 | -3.46 – -1.42 | 23 | 6.9% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -24.9%
- More than 10% revenue growth is expected for the coming year -70.6%
- Share count grows by less than 3% a year 44.6%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -9,334.0%
- Gross margin at 40% or higher and without meaningful erosion 78.5%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 45 m
- Return on capital at 15% or higher, or up versus two years ago -313.8%
- Insiders hold at least 10% or are net buyers 17.1%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% 979.4%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 979.4%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% -313.8%
- Expected return > 10% 600.9%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Matlin David J | Director | Other | 434,451 | 3.28 | 1,424,999 |
| Sep 16, 2026 | Etherington Robert Dee | President & CEO | Other | 15,244 | 3.28 | 50,000 |
| Sep 16, 2026 | Mosca Alison | Director | Other | 198,171 | 3.28 | 650,001 |
| Apr 21, 2026 | Chidozie Ugwumba | Major Shareholder | Sell | 61,345 | 6.14 | 376,658 |
| Apr 20, 2026 | Chidozie Ugwumba | Major Shareholder | Sell | 4,318 | 6.12 | 26,426 |
| Apr 17, 2026 | Chidozie Ugwumba | Major Shareholder | Sell | 25,040 | 6.43 | 161,007 |
The company
About the Company
Clene Inc., ein Pharmaunternehmen im klinischen Stadium, konzentriert sich auf die Entdeckung, Entwicklung und Vermarktung neuartiger Therapeutika auf Basis der Clean-Surfaced-Nanotechnologie (CSN). Der führende Wirkstoffkandidat des Unternehmens ist CNM-Au8, der in verschiedenen klinischen Studien untersucht wird, darunter eine abgeschlossene Phase-2-Plattformstudie zur Bewertung der Sicherheit und Wirksamkeit von CNM-Au8 bei Patienten mit amyotropher Lateralsklerose (ALS); eine abgeschlossene Phase-2-Konzeptnachweisstudie bei Patienten mit früher symptomatischer ALS; zwei abgeschlossene offene, für den Prüfarzt verblindete Phase-2-Studien zu den Energiemetaboliten des Gehirns; eine abgeschlossene Phase-2-Studie zur Behandlung von Defiziten der Sehbahn bei chronischer Optikusneuropathie zur Remyelinisierung bei stabiler schubförmiger Multipler Sklerose; und eine zweite Phase-2-Studie zur Behandlung von Patienten mit Parkinson-Krankheit. Es entwickelt CNM-AgZn17, eine Gel-Polymer-Suspension aus Silber- und Zinkionen, die zur Behandlung von Infektionskrankheiten und zur Unterstützung der Wundheilung entwickelt wird; sowie CNM-ZnAg, ein antivirales und antibakterielles Breitbandmittel zur Behandlung von Infektionskrankheiten und zur immunologischen Unterstützung der Symptomlösung. Darüber hinaus vermarktet und vertreibt das Unternehmen Nahrungsergänzungsmittel, darunter rMetx, ein wässriges Zink-Silber-Ionen-Nahrungsergänzungsmittel, und KHC46, ein wässriges Gold-Nahrungsergänzungsmittel mit sehr niedrig konzentrierten Au-Nanopartikeln. Clene Inc. hat seinen Hauptsitz in Salt Lake City, Utah.
- Employees
- 76
- Headquarters
- Salt Lake City, UT
- Address
- 6550 South Millrock Drive, 84121 Salt Lake City, United States
- Phone
- 801 676 9695
- Website
- clene.com
- IPO Date
- 12/31/2020
- ISIN
- US1856342019
- Stock Split
- 1:20 on 07/11/2024
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert Etherington MBA | CEO, President & Director | 1967 |
| Morgan R. Brown CPA, M.B.A. | Chief Financial Officer | 1968 |
| Mark G. Mortenson ESQ. | Chief Science Officer | 1958 |
| Jerry Miraglia J.D. | General Counsel & Corporate Secretary | – |
| Mary Anne Mcneil | Head of Human Resources | – |
| Michael T. Hotchkin | Chief Development Officer | – |
| Benjamin M. Greenberg M.D., M.H.S. | Head of Medical | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.